Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma.

Decaudin D, Frisch Dit Leitz E, Nemati F, Tarin M, Naguez A, Zerara M, Marande B, Vivet-Noguer R, Halilovic E, Fabre C, Jochemsen A, Roman-Roman S, Alsafadi S.

Eur J Cancer. 2020 Feb;126:93-103. doi: 10.1016/j.ejca.2019.12.012. Epub 2020 Jan 9.

2.

NEK11 as a candidate high-penetrance melanoma susceptibility gene.

Christodoulou E, van Doorn R, Visser M, Teunisse A, Versluis M, van der Velden P, Hayward NK, Jochemsen A, Gruis N.

J Med Genet. 2019 Nov 8. pii: jmedgenet-2019-106134. doi: 10.1136/jmedgenet-2019-106134. [Epub ahead of print]

PMID:
31704778
3.

A novel germline variant in the DOT1L gene co-segregating in a Dutch family with a history of melanoma.

Salgado C, Kwesi-Maliepaard EM, Jochemsen AG, Visser M, Harland M, van Leeuwen F, van Doorn R, Gruis N.

Melanoma Res. 2019 Dec;29(6):582-589. doi: 10.1097/CMR.0000000000000640.

PMID:
31524790
4.

HLA Expression in Uveal Melanoma: An Indicator of Malignancy and a Modifiable Immunological Target.

Souri Z, Wierenga APA, Mulder A, Jochemsen AG, Jager MJ.

Cancers (Basel). 2019 Aug 7;11(8). pii: E1132. doi: 10.3390/cancers11081132. Review.

5.

Differential Expression of DNA Repair Genes in Prognostically-Favorable versus Unfavorable Uveal Melanoma.

Dogrusöz M, Ruschel Trasel A, Cao J, Ҫolak S, van Pelt SI, Kroes WGM, Teunisse AFAS, Alsafadi S, van Duinen SG, Luyten GPM, van der Velden PA, Amaro A, Pfeffer U, Jochemsen AG, Jager MJ.

Cancers (Basel). 2019 Aug 2;11(8). pii: E1104. doi: 10.3390/cancers11081104.

6.

Loss of BAP1 Is Associated with Upregulation of the NFkB Pathway and Increased HLA Class I Expression in Uveal Melanoma.

Souri Z, Wierenga APA, van Weeghel C, van der Velden PA, Kroes WGM, Luyten GPM, van der Burg SH, Jochemsen AG, Jager MJ.

Cancers (Basel). 2019 Aug 2;11(8). pii: E1102. doi: 10.3390/cancers11081102.

7.

So Close, yet so Far: Discrepancies between Uveal and Other Melanomas. A Position Paper from UM Cure 2020.

Rodrigues M, Koning L, Coupland SE, Jochemsen AG, Marais R, Stern MH, Valente A, Barnhill R, Cassoux N, Evans A, Galloway I, Jager MJ, Kapiteijn E, Romanowska-Dixon B, Ryll B, Roman-Roman S, Piperno-Neumann S; UM Cure 2020 Consortium.

Cancers (Basel). 2019 Jul 22;11(7). pii: E1032. doi: 10.3390/cancers11071032.

8.

Correction for Danovi et al., "Amplification of Mdmx (or Mdm4) Directly Contributes to Tumor Formation by Inhibiting p53 Tumor Suppressor Activity".

Danovi D, Meulmeester E, Pasini D, Migliorini D, Capra M, Frenk R, de Graaf P, Francoz S, Gasparini P, Gobbi A, Helin K, Pelicci PG, Jochemsen AG, Marine JC.

Mol Cell Biol. 2019 Jul 16;39(15). pii: e00150-19. doi: 10.1128/MCB.00150-19. Print 2019 Aug 1. No abstract available.

9.

Selective PKCδ Inhibitor B106 Elicits Uveal Melanoma Growth Inhibitory Effects Independent of Activated PKC Isoforms.

Heijkants R, Teunisse A, de Vries J, Ovaa H, Jochemsen A.

ACS Chem Biol. 2019 Jan 18;14(1):132-136. doi: 10.1021/acschembio.8b00292. Epub 2019 Jan 2.

PMID:
30525429
10.

Overexpression of EZH2 in conjunctival melanoma offers a new therapeutic target.

Cao J, Pontes KC, Heijkants RC, Brouwer NJ, Groenewoud A, Jordanova ES, Marinkovic M, van Duinen S, Teunisse AF, Verdijk RM, Snaar-Jagalska E, Jochemsen AG, Jager MJ.

J Pathol. 2018 Aug;245(4):433-444. doi: 10.1002/path.5094. Epub 2018 Jun 23.

11.

Targeting MDMX and PKCδ to improve current uveal melanoma therapeutic strategies.

Heijkants RC, Nieveen M, Hart KC', Teunisse AFAS, Jochemsen AG.

Oncogenesis. 2018 Mar 29;7(3):33. doi: 10.1038/s41389-018-0041-y.

12.

Combined inhibition of CDK and HDAC as a promising therapeutic strategy for both cutaneous and uveal metastatic melanoma.

Heijkants R, Willekens K, Schoonderwoerd M, Teunisse A, Nieveen M, Radaelli E, Hawinkels L, Marine JC, Jochemsen A.

Oncotarget. 2017 Dec 15;9(5):6174-6187. doi: 10.18632/oncotarget.23485. eCollection 2018 Jan 19.

13.

Functional analyses of a human vascular tumor FOS variant identify a novel degradation mechanism and a link to tumorigenesis.

van IJzendoorn DGP, Forghany Z, Liebelt F, Vertegaal AC, Jochemsen AG, Bovée JVMG, Szuhai K, Baker DA.

J Biol Chem. 2017 Dec 29;292(52):21282-21290. doi: 10.1074/jbc.C117.815845. Epub 2017 Nov 17.

14.

Fluorescent CXCR4 targeting peptide as alternative for antibody staining in Ewing sarcoma.

Sand LGL, Buckle T, van Leeuwen FWB, Corver WE, Kruisselbrink AB, Jochemsen AG, Hogendoorn PCW, Szuhai K.

BMC Cancer. 2017 May 26;17(1):383. doi: 10.1186/s12885-017-3352-z.

15.

MDM4 is a rational target for treating breast cancers with mutant p53.

Miranda PJ, Buckley D, Raghu D, Pang JB, Takano EA, Vijayakumaran R, Teunisse AF, Posner A, Procter T, Herold MJ, Gamell C, Marine JC, Fox SB, Jochemsen A, Haupt S, Haupt Y.

J Pathol. 2017 Apr;241(5):661-670. doi: 10.1002/path.4877. Epub 2017 Mar 1.

PMID:
28097652
16.

Targeting of the MAPK and AKT pathways in conjunctival melanoma shows potential synergy.

Cao J, Heijkants RC, Jochemsen AG, Dogrusöz M, de Lange MJ, van der Velden PA, van der Burg SH, Jager MJ, Verdijk RM.

Oncotarget. 2016 Jul 22;8(35):58021-58036. doi: 10.18632/oncotarget.10770. eCollection 2017 Aug 29.

17.

MDMX (MDM4), a Promising Target for p53 Reactivation Therapy and Beyond.

Marine JC, Jochemsen AG.

Cold Spring Harb Perspect Med. 2016 Jul 1;6(7). pii: a026237. doi: 10.1101/cshperspect.a026237. Review.

18.

Embryonic Zebrafish: Different Phenotypes after Injection of Human Uveal Melanoma Cells.

van der Ent W, Burrello C, de Lange MJ, van der Velden PA, Jochemsen AG, Jager MJ, Snaar-Jagalska BE.

Ocul Oncol Pathol. 2015 Apr;1(3):170-81. doi: 10.1159/000370159. Epub 2015 Apr 9. Review.

19.

Novel splice variants of CXCR4 identified by transcriptome sequencing.

Sand LG, Jochemsen AG, Beletkaia E, Schmidt T, Hogendoorn PC, Szuhai K.

Biochem Biophys Res Commun. 2015 Oct 9;466(1):89-94. doi: 10.1016/j.bbrc.2015.08.113. Epub 2015 Aug 28.

PMID:
26321665
20.

Targeting Mdmx to treat breast cancers with wild-type p53.

Haupt S, Buckley D, Pang JM, Panimaya J, Paul PJ, Gamell C, Takano EA, Lee YY, Hiddingh S, Rogers TM, Teunisse AF, Herold MJ, Marine JC, Fox SB, Jochemsen A, Haupt Y.

Cell Death Dis. 2015 Jul 16;6:e1821. doi: 10.1038/cddis.2015.173.

21.

Interaction between p53 mutation and a somatic HDMX biomarker better defines metastatic potential in breast cancer.

Grawenda AM, Møller EK, Lam S, Repapi E, Teunisse AF, Alnæs GI, Børresen-Dale AL, Kristensen VN, Goding CR, Jochemsen AG, Edvardsen H, Bond GL.

Cancer Res. 2015 Feb 15;75(4):698-708. doi: 10.1158/0008-5472.CAN-14-2637. Epub 2015 Feb 3.

22.

Wild-type p53 inhibits pro-invasive properties of TGF-β3 in breast cancer, in part through regulation of EPHB2, a new TGF-β target gene.

Lam S, Wiercinska E, Teunisse AF, Lodder K, ten Dijke P, Jochemsen AG.

Breast Cancer Res Treat. 2014 Nov;148(1):7-18. doi: 10.1007/s10549-014-3147-8. Epub 2014 Sep 26.

PMID:
25257729
23.

Modeling of human uveal melanoma in zebrafish xenograft embryos.

van der Ent W, Burrello C, Teunisse AF, Ksander BR, van der Velden PA, Jager MJ, Jochemsen AG, Snaar-Jagalska BE.

Invest Ophthalmol Vis Sci. 2014 Sep 23;55(10):6612-22. doi: 10.1167/iovs.14-15202.

PMID:
25249605
24.

Mice engineered for an obligatory Mdm4 exon skipping express higher levels of the Mdm4-S isoform but exhibit increased p53 activity.

Bardot B, Bouarich-Bourimi R, Leemput J, Lejour V, Hamon A, Plancke L, Jochemsen AG, Simeonova I, Fang M, Toledo F.

Oncogene. 2015 May 28;34(22):2943-8. doi: 10.1038/onc.2014.230. Epub 2014 Aug 4.

PMID:
25088193
25.

Ewing sarcoma inhibition by disruption of EWSR1-FLI1 transcriptional activity and reactivation of p53.

van der Ent W, Jochemsen AG, Teunisse AF, Krens SF, Szuhai K, Spaink HP, Hogendoorn PC, Snaar-Jagalska BE.

J Pathol. 2014 Aug;233(4):415-24. doi: 10.1002/path.4378. Epub 2014 Jun 27.

PMID:
24974828
26.

The clinical development of p53-reactivating drugs in sarcomas - charting future therapeutic approaches and understanding the clinical molecular toxicology of Nutlins.

Biswas S, Killick E, Jochemsen AG, Lunec J.

Expert Opin Investig Drugs. 2014 May;23(5):629-45. doi: 10.1517/13543784.2014.892924. Epub 2014 Feb 28. Review.

PMID:
24579771
27.

Reactivation of p53 as therapeutic intervention for malignant melanoma.

Jochemsen AG.

Curr Opin Oncol. 2014 Jan;26(1):114-9. doi: 10.1097/CCO.0000000000000033. Review.

PMID:
24275854
28.

p53 promotes VEGF expression and angiogenesis in the absence of an intact p21-Rb pathway.

Farhang Ghahremani M, Goossens S, Nittner D, Bisteau X, Bartunkova S, Zwolinska A, Hulpiau P, Haigh K, Haenebalcke L, Drogat B, Jochemsen A, Roger PP, Marine JC, Haigh JJ.

Cell Death Differ. 2013 Jul;20(7):888-97. doi: 10.1038/cdd.2013.12. Epub 2013 Mar 1.

29.

RNF4 is required for DNA double-strand break repair in vivo.

Vyas R, Kumar R, Clermont F, Helfricht A, Kalev P, Sotiropoulou P, Hendriks IA, Radaelli E, Hochepied T, Blanpain C, Sablina A, van Attikum H, Olsen JV, Jochemsen AG, Vertegaal AC, Marine JC.

Cell Death Differ. 2013 Mar;20(3):490-502. doi: 10.1038/cdd.2012.145. Epub 2012 Nov 30.

30.

High levels of Hdmx promote cell growth in a subset of uveal melanomas.

de Lange J, Teunisse AF, Vries MV, Lodder K, Lam S, Luyten GP, Bernal F, Jager MJ, Jochemsen AG.

Am J Cancer Res. 2012;2(5):492-507. Epub 2012 Aug 20.

31.

Synthetic lethality between Rb, p53 and Dicer or miR-17-92 in retinal progenitors suppresses retinoblastoma formation.

Nittner D, Lambertz I, Clermont F, Mestdagh P, Köhler C, Nielsen SJ, Jochemsen A, Speleman F, Vandesompele J, Dyer MA, Schramm A, Schulte JH, Marine JC.

Nat Cell Biol. 2012 Sep;14(9):958-65. doi: 10.1038/ncb2556. Epub 2012 Aug 5.

PMID:
22864477
32.

MDM4 is a key therapeutic target in cutaneous melanoma.

Gembarska A, Luciani F, Fedele C, Russell EA, Dewaele M, Villar S, Zwolinska A, Haupt S, de Lange J, Yip D, Goydos J, Haigh JJ, Haupt Y, Larue L, Jochemsen A, Shi H, Moriceau G, Lo RS, Ghanem G, Shackleton M, Bernal F, Marine JC.

Nat Med. 2012 Aug;18(8):1239-47. doi: 10.1038/nm.2863. Epub 2012 Jul 22.

33.

Microarray-based identification of age-dependent differences in gene expression of human dermal fibroblasts.

Dekker P, Gunn D, McBryan T, Dirks RW, van Heemst D, Lim FL, Jochemsen AG, Verlaan-de Vries M, Nagel J, Adams PD, Tanke HJ, Westendorp RG, Maier AB.

Mech Ageing Dev. 2012 Jul;133(7):498-507. doi: 10.1016/j.mad.2012.06.002. Epub 2012 Jun 18.

PMID:
22721680
34.

Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer.

Lenos K, Grawenda AM, Lodder K, Kuijjer ML, Teunisse AF, Repapi E, Grochola LF, Bartel F, Hogendoorn PC, Wuerl P, Taubert H, Cleton-Jansen AM, Bond GL, Jochemsen AG.

Cancer Res. 2012 Aug 15;72(16):4074-84. Epub 2012 Jun 14.

35.

Mdmx: a p53 activator?

Jochemsen AG.

Cell Cycle. 2012 Mar 1;11(5):843. doi: 10.4161/cc.11.5.19597. Epub 2012 Mar 1. No abstract available.

PMID:
22356751
36.

Chk2 mediates RITA-induced apoptosis.

de Lange J, Verlaan-de Vries M, Teunisse AF, Jochemsen AG.

Cell Death Differ. 2012 Jun;19(6):980-9. doi: 10.1038/cdd.2011.182. Epub 2011 Dec 9.

37.

Oncogenic functions of hMDMX in in vitro transformation of primary human fibroblasts and embryonic retinoblasts.

Lenos K, de Lange J, Teunisse AF, Lodder K, Verlaan-de Vries M, Wiercinska E, van der Burg MJ, Szuhai K, Jochemsen AG.

Mol Cancer. 2011 Sep 12;10:111. doi: 10.1186/1476-4598-10-111.

38.

Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma.

de Lange J, Ly LV, Lodder K, Verlaan-de Vries M, Teunisse AF, Jager MJ, Jochemsen AG.

Oncogene. 2012 Mar 1;31(9):1105-16. doi: 10.1038/onc.2011.309. Epub 2011 Jul 18.

PMID:
21765463
40.

Abrogation of Wip1 expression by RITA-activated p53 potentiates apoptosis induction via activation of ATM and inhibition of HdmX.

Spinnler C, Hedström E, Li H, de Lange J, Nikulenkov F, Teunisse AF, Verlaan-de Vries M, Grinkevich V, Jochemsen AG, Selivanova G.

Cell Death Differ. 2011 Nov;18(11):1736-45. doi: 10.1038/cdd.2011.45. Epub 2011 May 6.

41.

Functions of MDMX in the modulation of the p53-response.

Lenos K, Jochemsen AG.

J Biomed Biotechnol. 2011;2011:876173. doi: 10.1155/2011/876173. Epub 2011 Mar 22. Review.

42.

HDMX-L is expressed from a functional p53-responsive promoter in the first intron of the HDMX gene and participates in an autoregulatory feedback loop to control p53 activity.

Phillips A, Teunisse A, Lam S, Lodder K, Darley M, Emaduddin M, Wolf A, Richter J, de Lange J, Verlaan-de Vries M, Lenos K, Böhnke A, Bartel F, Blaydes JP, Jochemsen AG.

J Biol Chem. 2010 Sep 17;285(38):29111-27. doi: 10.1074/jbc.M110.129726. Epub 2010 Jul 20.

43.

USP10: friend and foe.

Jochemsen AG, Shiloh Y.

Cell. 2010 Feb 5;140(3):308-10. doi: 10.1016/j.cell.2010.01.034.

44.

Role of Mdm4 in drug sensitivity of breast cancer cells.

Lam S, Lodder K, Teunisse AF, Rabelink MJ, Schutte M, Jochemsen AG.

Oncogene. 2010 Apr 22;29(16):2415-26. doi: 10.1038/onc.2009.522. Epub 2010 Feb 8.

PMID:
20140020
45.

Identification and characterization of the first small molecule inhibitor of MDMX.

Reed D, Shen Y, Shelat AA, Arnold LA, Ferreira AM, Zhu F, Mills N, Smithson DC, Regni CA, Bashford D, Cicero SA, Schulman BA, Jochemsen AG, Guy RK, Dyer MA.

J Biol Chem. 2010 Apr 2;285(14):10786-96. doi: 10.1074/jbc.M109.056747. Epub 2010 Jan 15.

46.

Phosphorylation and degradation of MdmX is inhibited by Wip1 phosphatase in the DNA damage response.

Zhang X, Lin L, Guo H, Yang J, Jones SN, Jochemsen A, Lu X.

Cancer Res. 2009 Oct 15;69(20):7960-8. doi: 10.1158/0008-5472.CAN-09-0634. Epub 2009 Oct 6.

47.

Macrophage p53 controls macrophage death in atherosclerotic lesions of apolipoprotein E deficient mice.

Boesten LS, Zadelaar AS, van Nieuwkoop A, Hu L, Teunisse AF, Jochemsen AG, Evers B, van de Water B, Gijbels MJ, van Vlijmen BJ, Havekes LM, de Winther MP.

Atherosclerosis. 2009 Dec;207(2):399-404. doi: 10.1016/j.atherosclerosis.2009.06.015. Epub 2009 Jun 18.

PMID:
19608184
48.

Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.

Hollestelle A, Nagel JH, Smid M, Lam S, Elstrodt F, Wasielewski M, Ng SS, French PJ, Peeters JK, Rozendaal MJ, Riaz M, Koopman DG, Ten Hagen TL, de Leeuw BH, Zwarthoff EC, Teunisse A, van der Spek PJ, Klijn JG, Dinjens WN, Ethier SP, Clevers H, Jochemsen AG, den Bakker MA, Foekens JA, Martens JW, Schutte M.

Breast Cancer Res Treat. 2010 May;121(1):53-64. doi: 10.1007/s10549-009-0460-8. Epub 2009 Jul 11.

PMID:
19593635
49.

Increased radioresistance and accelerated B cell lymphomas in mice with Mdmx mutations that prevent modifications by DNA-damage-activated kinases.

Wang YV, Leblanc M, Wade M, Jochemsen AG, Wahl GM.

Cancer Cell. 2009 Jul 7;16(1):33-43. doi: 10.1016/j.ccr.2009.05.008.

50.

Cytoplasmic tethering is involved in synergistic inhibition of p53 by Mdmx and Mdm2.

Ohtsubo C, Shiokawa D, Kodama M, Gaiddon C, Nakagama H, Jochemsen AG, Taya Y, Okamoto K.

Cancer Sci. 2009 Jul;100(7):1291-9. doi: 10.1111/j.1349-7006.2009.01180.x. Epub 2009 Apr 27.

Supplemental Content

Loading ...
Support Center